Skip to main content
    I

    Immunic Inc (IMUX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.23
    -0.29 (-3.86%)

    Market Cap: $102.61M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immunic Inc (IMUX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Immunic reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$97.17M, operating cash flow was -$85.81M and free cash flow was -$85.97M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$42.31M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $103.23M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$81.98M$80.05M$83.22M$71.25M$61.12M$38.64M$22.51M$9.60M$39.34M$30.05M
    Operating income-$103.23M-$98.05M-$99.22M-$119.49M-$91.67M-$48.97M-$37.03M-$12.00M-$52.66M-$41.27M
    Net income-$97.17M-$100.51M-$93.61M-$120.41M-$92.94M-$44.02M-$34.93M-$11.54M-$52.08M-$40.97M
    EBITDA-$98.04MN/A-$96.58MN/AN/A-$44.04M-$34.99M-$11.53M-$51.73M-$39.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$114.00K$0$0$0$0
    Gross profit$0$0$0-$42.00K$0$0$0-$35.00K$0$0$0-$23.00K
    Operating income-$43.37M-$35.33M-$33.23M-$23.33M-$25.99M-$27.08M-$26.82M-$25.63M-$25.73M-$22.81M-$23.88M-$23.38M
    Net income-$42.31M-$34.10M-$32.59M-$19.30M-$25.58M-$26.82M-$25.47M-$25.18M-$24.37M-$21.38M-$29.58M-$21.57M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $470.00K by $15.01M. Shareholder equity was negative, at -$6.67M, as total liabilities of $30.73M exceeded total assets of $24.05M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$24.05M$40.87M$54.30M$127.75M$139.10M$167.86M$65.95M$13.37M$60.38M$64.03M
    Current assets$22.87M$39.33M$52.53M$125.86M$104.99M$133.75M$32.23M$13.33M$58.12M$61.46M
    Cash and equivalents$15.48M$35.67M$46.67M$106.75M$86.86M$127.45M$29.37M$13.07M$56.90M$59.99M
    Total liabilities$30.73M$22.44M$25.37M$14.07M$11.98M$9.08M$7.59M$1.92M$10.34M$5.58M
    Short-term debt$470.00K$740.00K$695.00K$571.00K$408.00K$297.00K$3.30MN/A$0$0
    Shareholder equity-$6.67M$18.43M$28.93M$113.68M$127.11M$158.78M$58.36M-$25.74M$50.04M$58.45M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$136.42M$159.17M$189.74M$24.05M$40.70M$61.43M$20.52M$40.87M$64.76M$86.49M$104.16M$54.30M
    Total liabilities$31.95M$31.59M$38.51M$30.73M$30.20M$27.52M$25.80M$22.44M$23.54M$22.92M$20.58M$25.37M
    Cash and equivalents$131.96M$155.10M$186.63M$15.48M$35.13M$55.31M$14.30M$35.67M$59.07M$79.70M$97.31M$46.67M
    Shareholder equity$104.47M$127.58M$151.23M-$6.67M$10.50M$33.91M-$5.29M$18.43M$41.22M$63.57M$83.58M$28.93M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$85.81M-$84.77M-$70.83M-$65.14M-$83.23M-$46.12M-$28.55M-$9.74M-$40.40M-$35.77M
    Capital expenditures$161.00K$264.00K$334.00K$112.00K$67.00K$146.00K$55.00K$32.00K$685.00K$556.00K
    Free cash flow-$85.97M-$85.03M-$71.16M-$65.26M-$83.30M-$46.27M-$28.60M-$9.77M-$41.08M-$36.33M
    Investing cash flow-$161.00K-$264.00K$9.46M-$9.74M-$67.00K-$146.00K$10.54M-$32.00K-$678.00K-$21.00K
    Financing cash flow$65.58M$74.54M$1.03M$95.76M$42.84M$144.43M$34.90M$19.26M$37.98M$12.37M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$28.39M-$31.00M-$17.30M-$19.28M-$20.14M-$24.61M-$21.78M-$22.96M-$20.80M-$17.04M-$23.97M-$14.03M
    Capital expenditures$104.00K$249.00K$2.00K$11.00K$67.00K$36.00K$47.00K$3.00K$50.00K$180.00K$31.00K$165.00K
    Free cash flow-$28.49M-$31.25M-$17.30M-$19.29M-$20.21M-$24.64M-$21.82M-$22.97M-$20.84M-$17.22M-$24.00M-$14.19M
    Last 12 quarters

    Frequently Asked Questions About IMUX

    What is Immunic's annual revenue?

    Immunic reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Immunic profitable?

    No. Immunic reported net income of -$97.17M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does IMUX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$85.81M minus capital expenditures of $161.00K produced free cash flow of -$85.97M.

    How much debt does Immunic have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $470.00K and cash and equivalents of $15.48M.